Literature DB >> 22935759

The determination and interpretation of the therapeutic index in drug development.

Patrick Y Muller1, Mark N Milton.   

Abstract

A key part of drug discovery and development is the characterization and optimization of the safety and efficacy of drug candidates to identify those that have an appropriately balanced safety-efficacy profile for a given indication. The therapeutic index (TI)--which is typically considered as the ratio of the highest exposure to the drug that results in no toxicity to the exposure that produces the desired efficacy--is an important parameter in efforts to achieve this balance. Various types of safety and efficacy data are generated in vitro and in vivo (in animals and in humans), and these data can be used to predict the clinical TI of a drug candidate at an early stage. However, approaches to systematically and quantitatively compare these types of data and to apply this knowledge more effectively are needed. This article critically discusses the various aspects of TI determination and interpretation in drug development for both small molecule drugs and biotherapeutics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22935759     DOI: 10.1038/nrd3801

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  42 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.

Authors:  Andreas Bender; Josef Scheiber; Meir Glick; John W Davies; Kamal Azzaoui; Jacques Hamon; Laszlo Urban; Steven Whitebread; Jeremy L Jenkins
Journal:  ChemMedChem       Date:  2007-06       Impact factor: 3.466

Review 3.  Genomic and proteomic approaches for predicting toxicity and adverse drug reactions.

Authors:  Feng Ge; Qing-Yu He
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-01       Impact factor: 4.481

4.  The use of C(av) rather than AUC in safety assessment.

Authors:  D A Smith; P Morgan; W M Vogel; D K Walker
Journal:  Regul Toxicol Pharmacol       Date:  2010-01-13       Impact factor: 3.271

Review 5.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

Review 6.  Native albumin for targeted drug delivery.

Authors:  Elena Neumann; Eva Frei; Dorothee Funk; Matthias D Becker; Hans-Hermann Schrenk; Ulf Müller-Ladner; Christoph Fiehn
Journal:  Expert Opin Drug Deliv       Date:  2010-08       Impact factor: 6.648

Review 7.  Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors.

Authors:  P L Toutain; H P Lefèbvre
Journal:  J Vet Pharmacol Ther       Date:  2004-12       Impact factor: 1.786

Review 8.  Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.

Authors:  P Y Muller; F R Brennan
Journal:  Clin Pharmacol Ther       Date:  2009-01-28       Impact factor: 6.875

Review 9.  In silico prediction of drug toxicity.

Authors:  John C Dearden
Journal:  J Comput Aided Mol Des       Date:  2003 Feb-Apr       Impact factor: 3.686

Review 10.  Autoradiography, MALDI-MS, and SIMS-MS imaging in pharmaceutical discovery and development.

Authors:  Eric G Solon; Alain Schweitzer; Markus Stoeckli; Brendan Prideaux
Journal:  AAPS J       Date:  2009-11-17       Impact factor: 4.009

View more
  117 in total

Review 1.  The human endogenous metabolome as a pharmacology baseline for drug discovery.

Authors:  Andreu Bofill; Xavier Jalencas; Tudor I Oprea; Jordi Mestres
Journal:  Drug Discov Today       Date:  2019-06-19       Impact factor: 7.851

Review 2.  Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.

Authors:  Aman P Singh; Young G Shin; Dhaval K Shah
Journal:  Pharm Res       Date:  2015-02-11       Impact factor: 4.200

Review 3.  Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.

Authors:  Lucas Moreno; Andrew D J Pearson; Xavier Paoletti; Irene Jimenez; Birgit Geoerger; Pamela R Kearns; C Michel Zwaan; Francois Doz; Andre Baruchel; Josef Vormoor; Michela Casanova; Stefan M Pfister; Bruce Morland; Gilles Vassal
Journal:  Nat Rev Clin Oncol       Date:  2017-05-16       Impact factor: 66.675

4.  Antiviral Activity of Nordihydroguaiaretic Acid and Its Derivative Tetra-O-Methyl Nordihydroguaiaretic Acid against West Nile Virus and Zika Virus.

Authors:  Teresa Merino-Ramos; Nereida Jiménez de Oya; Juan-Carlos Saiz; Miguel A Martín-Acebes
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 5.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling.

Authors:  Joanne Bowes; Andrew J Brown; Jacques Hamon; Wolfgang Jarolimek; Arun Sridhar; Gareth Waldron; Steven Whitebread
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

6.  Antimicrobial action of 1,10-phenanthroline-based compounds on carbapenemase-producing Acinetobacter baumannii clinical strains: efficacy against planktonic- and biofilm-growing cells.

Authors:  Roberta F Ventura; Anna Clara M Galdino; Livia Viganor; Ricardo P Schuenck; Michael Devereux; Malachy McCann; André L S Santos; Ana Paula F Nunes
Journal:  Braz J Microbiol       Date:  2020-07-31       Impact factor: 2.476

7.  Antitubercular activity of 1,2,3-triazolyl fatty acid derivatives.

Authors:  Diego G Ghiano; Agustina de la Iglesia; Nina Liu; Peter J Tonge; Héctor R Morbidoni; Guillermo R Labadie
Journal:  Eur J Med Chem       Date:  2016-09-28       Impact factor: 6.514

8.  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.

Authors:  Carolin Sellmann; Achim Doerner; Christine Knuehl; Nicolas Rasche; Vanita Sood; Simon Krah; Laura Rhiel; Annika Messemer; John Wesolowski; Mark Schuette; Stefan Becker; Lars Toleikis; Harald Kolmar; Bjoern Hock
Journal:  J Biol Chem       Date:  2016-09-30       Impact factor: 5.157

Review 9.  Paradigm shift in bacteriophage-mediated delivery of anticancer drugs: from targeted 'magic bullets' to self-navigated 'magic missiles'.

Authors:  Valery A Petrenko; James W Gillespie
Journal:  Expert Opin Drug Deliv       Date:  2016-08-05       Impact factor: 6.648

10.  In Vitro Screening of the Open-Source Medicines for Malaria Venture Malaria Box Reveals Novel Compounds with Profound Activities against Theileria annulata Schizonts.

Authors:  Isabel Hostettler; Joachim Müller; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.